AstraZeneca to invest over $1 billion in Massachusetts, boost workforce AstraZeneca said on Monday it would spend more than $1 billion in Massachusetts as part of its broader $50 billion US ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Eli Lilly (LLY) earns a BUY rating with a $1,220 price target, backed by 47% revenue growth and four straight EPS beats. Novo Nordisk (NVO) trades at a forward P/E of 14 with just 2% revenue growth, ...

The label expansion builds on Inluriyo’s existing monotherapy indication, approved about a year ago. (Angus Liu/Fierce Pharma) Eli Lilly is sharpening its competitive edge in the crowded oral SERD ...

NVDA posted 106% revenue growth to $96B last quarter while LLY grew 48% to $23B, yet NVIDIA trades at just 23x forward earnings against a 60% operating margin. Jensen Huang projects 70% revenue growth ...

If you look at Eli Lilly's second-quarter revenues, you come away with a very clear picture of the pharmaceutical company's business. Mounjaro, Zepbound, and Foundayo account for nearly two-thirds of ...

Eli Lilly demonstrates superior operating momentum, volume growth, and late-stage obesity assets, justifying its current industry leadership. Both LLY and Novo Nordisk are rated Hold; NVO offers lower ...

Eli Lilly (NYSE: LLY) and Merck (NYSE: MRK) both just posted second quarter results, and the split screen is telling. Lilly is compounding on an incretin franchise that keeps widening. Merck is racing ...

The obesity-drug market is now moving to a much more complicated phase. The first major battle was largely fought between two obesity injectable GLP-1 drugs, Eli Lilly's (LLY) Zepbound and Novo's (NVO ...

Canadian biotech QurCan Therapeutics on Tuesday announced an investment from Eli Lilly (LLY) as part of an exclusive research and collaboration agreement with the Indiana-based pharma giant to develop ...

Lilly still boasts a robust pipeline of next-gen obesity candidates, led by retatrutide. (iStock / Getty Images Plus) Eli Lilly has put the kibosh on an early-stage obesity drug after the candidate ...